Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kathleen Hawker

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Current Opinion in Neurology|June 17, 2008
B-cell-targeted treatment for multiple sclerosis: mechanism of action and clinical dataKathleen Hawker
Continuum (Minneapolis, Minn.)|July 20, 2012
Primary progressive multiple sclerosisKathleen Hawker
Annals of Indian Academy of Neurology|February 26, 2010
B cells as a target of immune modulationKathleen Hawker
Neurologic Clinics|March 29, 2011
Progressive multiple sclerosis: characteristics and managementKathleen Hawker
Primary Care|April 28, 2004
Multiple sclerosisKathleen Hawker, Elliot Frohman
Archives of Neurology|December 17, 2003
Levetiracetam for phasic spasticity in multiple sclerosisKathleen Hawker, Elliot Frohman, Michael Racke
Urology|May 11, 2005
Incidence of upper tract abnormalities in patients with neurovesical dysfunction secondary to multiple sclerosis: analysis of risk factors at initial urologic evaluationGary E Lemack, Kathleen Hawker, Elliot Frohman
Archives of Neurology|February 18, 2004
Fatigue in multiple sclerosis: is the picture getting simpler or more complex?Michael K Racke, Kathleen Hawker, Elliot M Frohman
Multiple Sclerosis and Related Disorders|July 27, 2016
Relapse rates in patients with multiple sclerosis treated with fingolimod: Subgroup analyses of pooled data from three phase 3 trialsTobias Derfuss, Daniel Ontaneda, Jacqueline Nicholas, et al.
Expert Review of Neurotherapeutics|November 21, 2015
Fingolimod: a review of its mode of action in the context of its efficacy and safety profile in relapsing forms of multiple sclerosisDouglas R Jeffery, Kottil W Rammohan, Kathleen Hawker, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Current Opinion in Neurology|June 17, 2008
B-cell-targeted treatment for multiple sclerosis: mechanism of action and clinical dataKathleen Hawker
Continuum (Minneapolis, Minn.)|July 20, 2012
Primary progressive multiple sclerosisKathleen Hawker
Annals of Indian Academy of Neurology|February 26, 2010
B cells as a target of immune modulationKathleen Hawker
Neurologic Clinics|March 29, 2011
Progressive multiple sclerosis: characteristics and managementKathleen Hawker
Primary Care|April 28, 2004
Multiple sclerosisKathleen Hawker, Elliot Frohman
Archives of Neurology|December 17, 2003
Levetiracetam for phasic spasticity in multiple sclerosisKathleen Hawker, Elliot Frohman, Michael Racke
Urology|May 11, 2005
Incidence of upper tract abnormalities in patients with neurovesical dysfunction secondary to multiple sclerosis: analysis of risk factors at initial urologic evaluationGary E Lemack, Kathleen Hawker, Elliot Frohman
Archives of Neurology|February 18, 2004
Fatigue in multiple sclerosis: is the picture getting simpler or more complex?Michael K Racke, Kathleen Hawker, Elliot M Frohman
Multiple Sclerosis and Related Disorders|July 27, 2016
Relapse rates in patients with multiple sclerosis treated with fingolimod: Subgroup analyses of pooled data from three phase 3 trialsTobias Derfuss, Daniel Ontaneda, Jacqueline Nicholas, et al.
Expert Review of Neurotherapeutics|November 21, 2015
Fingolimod: a review of its mode of action in the context of its efficacy and safety profile in relapsing forms of multiple sclerosisDouglas R Jeffery, Kottil W Rammohan, Kathleen Hawker, et al.
Pageof 2